RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has been recognized for excellence in all five categories in the 2024 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports and presented by Clinical Leader and Life Science Leader magazines. This marks the 11th consecutive year that Worldwide is rated as a high-performing CRO based on direct survey feedback from pharmaceutical and biotech professionals, with this year’s distinction augmented by additional honors as a Champion in several pivotal categories.
Highlights from the ISR data include Worldwide being named the highest rated service provider for Project Management Quality, outperforming all other Phase II/III CROs; achieving joint-first position for Operational Excellence among Phase II/III CROs; rating highest Phase II/III service provider for Biostatistics; and outperforming all other Phase II/III CROs for Project Service Delivery in Europe.
Worldwide achieved top marks from sponsor companies across all five core categories, demonstrating comprehensive excellence in:
- Capabilities (Overall, Big Pharma)
- Compatibility (Overall, Big Pharma, Small Pharma)
- Expertise (Overall, Big Pharma, Small Pharma)
- Quality (Overall, Big Pharma, Small Pharma)
- Reliability (Overall, Big Pharma, Small Pharma)
Additionally, Clinical Leader recognized organizations that surpassed the weighted average by more than one standard deviation in each of the core categories, earning them the ‘Champion’ title. Worldwide was honored as a Champion in:
- Compatibility (Big Pharma)
- Expertise (Big Pharma)
- Quality (Big Pharma)
- Reliability (Big Pharma)
"Worldwide's recognition as a top CRO underscores the dedication our team members have to exceed expectations through collaboration and a real understanding of what our customers want and need," said Peter Benton, president and CEO of Worldwide. "We are grateful for this industry acknowledgment, marking yet another milestone in our ongoing journey to improve patient lives through clinical research programs, and we remain committed to continued partnerships with our customers to drive innovation and meaningful advancement in healthcare."
Worldwide’s partnership approach with its customers is anchored in transparent communication, responsiveness, and personalized attention. Earlier this year, Worldwide released the results of its 2024 industry survey, a report that examines the changing perceptions about large and midsize CROs within the pharmaceutical and biotech sectors. The survey data revealed current challenges sponsors are facing with large CROs while highlighting the importance of CRO partnerships and flexibility – underscoring the benefits of Worldwide’s business model. Learn more here.
The CRO Leadership Awards serve as a beacon of trust and quality within the pharmaceutical industry, helping stakeholders identify CRO partners that are not just capable, but exemplary. This year's awards saw evaluations of 42 contract research organizations across over 20 performance metrics, grounded in robust, direct feedback from customers regarding their experiences over the past 18 months to reflect real-world performance and reliability.
Learn more about Worldwide’s services and achievements here.
About Worldwide Clinical Trials:
Worldwide Clinical Trials (Worldwide) is a leading full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.
